Contact Activation, Heparins and Cardiopulmonary Bypass

M J Gallimore; W Heller; G Fuhrer; H Wendel; R Klaffschenkel; H-E Hoffmeister

doi:10.1055/s-0038-1656327

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1992; 68(01): 091-092
DOI: 10.1055/s-0038-1656327

Letters to the Editor

Schattauer GmbH Stuttgart

Contact Activation, Heparins and Cardiopulmonary Bypass

M J Gallimore

Abt. für Herz, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany

,

W Heller

Abt. für Herz, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany

,

G Fuhrer

Abt. für Herz, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany

,

H Wendel

Abt. für Herz, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany

,

R Klaffschenkel

Abt. für Herz, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany

,

H-E Hoffmeister

Abt. für Herz, Thorax- und Gefäßchirurgie, Universität Tübingen, Tübingen, Germany

› Author Affiliations

Abstract

PDF Download

PDF (937 kb)

References

References
1 Pixley RA, Cassello A, De La Cadena RA, Kaufman N, Colman RW. Effect of heparin on the activation of Factor XII and the contact system in plasma. Thromb Haemostas 1991; 66: 540-547
2 Fuhrer G, Gallimore MJ, Heller W, Hoffmeister H-E. Studies on components of the plasma kallikrein-kinin system in patients undergoing cardiopulmonary bypass. Kinins IV. Advances in Experimental Medicine and Biology, vol 198 B. Plenum Press; New York: 1986: 385-391
3 Pixley RA, Schapira M, Colman RW. The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem 1985; 260: 1723-1729
4 De Agostini A, Linjen HR, Pixley RA, Colman RW, Schapira M. Inactivation of factor XII active fragment in normal plasma. Predominant role of C1-inhibitor. J Clin Invest 1984; 73: 1542-1549
5 Gallimore MJ, Amundsen E, Larsbraaten M, Lyngaas K, Fareid E. Studies on plasma inhibitors of plasma kallikrein using chromogenic peptide substrate assays. Thromb Res 1979; 16: 695-703
6 Schapira M. Major inhibitors of the contact phase coagulation factors. Semin Thromb Hemostas 1987; 13: 69-78
7 Amundsen E, Gallimore MJ, Aasen AO, Larsbraaten M, Lyngaas K. Activation of human plasma prekallikrein: Influence of activators, activation time and temperature and inhibitors. Thromb Res 1978; 13: 625-636
8 Fuhrer G, Gallimore MJ, Heller W, Hoffmeister H-E. Studies on the inhibition of plasma kallikrein, C1-esterase and beta FXIIa in the presence and absence of heparins. Kinins V. Advances in Experimental Medicine and Biology, vol 247 B.. Plenum Press; New York: 1989: 61-66
9 Gallimore MJ, Fuhrer G, Heller W, Hoffmeister H-E. The effects of fractionated and unfractionated heparins with and without aprotinin on plasma inhibition of alpha and beta FXIIa. KININ 91; Munich, Germany: 1991. abstract, PW-3.14, 226
10 Heller W, Fuhrer G, Hoberg S, Hoffmeister H-E, Philapitsch A. Effect of elevated C1-esterase inhibitor levels on elastase release in vitro. A proposed model for shock (ECC). First Vienna Shock Forum, Part A: Pathophysiological Role of Mediators and Mediator Inhibitors. Alan R Liss; New York: 1987: 107-114
11 Gallimore MJ, Fuhrer G, Heller W, Hoffmeister H-E. The effects of plasma kallikrein and beta FXIIa (FXIIf) on blood components circulating in a cardiopulmonary bypass machine. Thromb Haemostas 1989; 62: 268
12 Heller W, Wendel HP, Klaffschenkel R, Hoffmeister H-E. A comparative study of fractionated and unfractionated heparins on components of the FXII-plasma kallikrein system in an in vitro cardiopulmonary bypass model. KININ 91; Munich, Germany: 1991. abstract PW-3.15 227
13 Hunt BJ, Jacoub M. Aprotinin and cardiac surgery. Br Med J 1991; 303: 660-661